Enter your email address
Submit
Write your message
Volume 18, Issue 3 (Iranian Journal of Breast Diseases 2025)
ijbd 2025, 18(3): 85-99 |
Back to browse issues page
Ethics code: Ref 1: date:2025/05/01
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
A.G. AL Ghuraibawi Z, Muslem Hade I, Abd AL-Hussain Mahdi A, Majid Alkhaiat M, Ghazi Sadeq Z. Association Between Serum Interleukin-41 Levels and Breast Cancer Status: A Case–Control Study in Iraqi Women. ijbd 2025; 18 (3) :85-99
URL: http://ijbd.ir/article-1-1175-en.html
URL: http://ijbd.ir/article-1-1175-en.html
Zahraa A.G. AL Ghuraibawi1 
, Istikrar Muslem Hade1 , Ali Abd AL-Hussain Mahdi2 , Mareym Majid Alkhaiat *3 , Zainab Ghazi Sadeq4
, Istikrar Muslem Hade1 , Ali Abd AL-Hussain Mahdi2 , Mareym Majid Alkhaiat *3 , Zainab Ghazi Sadeq4
1- Iraqi National Cancer Research Center, University of Baghdad, Iraq
2- Middle Technical University, Baghdad, Iraq
3- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq ,maryam.m@nhm.uobaghdad.edu.iq
4- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq
2- Middle Technical University, Baghdad, Iraq
3- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq ,
4- Iraq Natural History Research Center and Museum, University of Baghdad, Iraq
Abstract: (271 Views)
Introduction: Breast cancer is the most common malignancy among women worldwide. Interleukin-41 (IL-41) is a novel cytokine with immunomodulatory functions. This study aimed to evaluate serum IL-41 levels in breast cancer patients compared with healthy women.
Methods: A case–control study was conducted on 60 breast cancer patients (20–41 y) and 30 healthy age-matched women (20–40 y) recruited from the Teaching Oncology Hospital, Baghdad (Dec 2023–Mar 2024). Demographic data were recorded. Serum IL-41 was measured using ELISA; liver enzymes GOT and GPT were assessed by spectrophotometry. Mann–Whitney U test and Cliff’s delta were used for analysis.
Results: Median IL-41 levels were significantly higher in patients compared to controls (p<0.001, Δ=0.75; p=0.002, Δ=0.80). GPT was also elevated in patients (p=0.004, Δ=0.45; p=0.01, Δ=0.60), while GOT showed no significant difference (p>0.05).
Conclusion: IL-41 may serve as a promising biomarker for breast cancer independent of age. Elevated GPT may indicate hepatic involvement. Further studies are required to validate these findings.
Methods: A case–control study was conducted on 60 breast cancer patients (20–41 y) and 30 healthy age-matched women (20–40 y) recruited from the Teaching Oncology Hospital, Baghdad (Dec 2023–Mar 2024). Demographic data were recorded. Serum IL-41 was measured using ELISA; liver enzymes GOT and GPT were assessed by spectrophotometry. Mann–Whitney U test and Cliff’s delta were used for analysis.
Results: Median IL-41 levels were significantly higher in patients compared to controls (p<0.001, Δ=0.75; p=0.002, Δ=0.80). GPT was also elevated in patients (p=0.004, Δ=0.45; p=0.01, Δ=0.60), while GOT showed no significant difference (p>0.05).
Conclusion: IL-41 may serve as a promising biomarker for breast cancer independent of age. Elevated GPT may indicate hepatic involvement. Further studies are required to validate these findings.
Type of Study: Research |
Subject:
Diagnosis, treatment, rehabilitation
Received: 2025/03/15 | Accepted: 2025/08/26 | Published: 2025/10/2
Received: 2025/03/15 | Accepted: 2025/08/26 | Published: 2025/10/2
References
1. Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel). 2022;14(10):2569. doi: 10.3390/cancers14102569. [DOI:10.3390/cancers14102569] [PMID] []
2. American Cancer Society. Cancer facts & figures. 2019. Accessed October 2, 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf.
3. 'Sullivan CC, Loprinzi CL, Haddad TC. Updates in the evaluation and management of breast cancer. Mayo Clin Proc. 2018;93(6):794-807. doi: 10.1016/j.mayocp.2018.03.025. [DOI:10.1016/j.mayocp.2018.03.025] [PMID]
4. Hortobagyi GN, Connolly JL, D'Orsi CJ, et al. Breast. In: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2018:589-636.
5. Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of Breast Cancer. In: Mayrovitz HN, ed. Breast Cancer. Brisbane (AU): Exon Publications; August 6, 2022.
https://doi.org/10.36255/exon-publications-breast-cancer-nanomaterials [DOI:10.36255/exon-publications-breast-cancer-subtypes] [PMID]
6. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28(6):690-714. doi: 10.1016/j.ccell.2015.10.012. [DOI:10.1016/j.ccell.2015.10.012] [PMID]
7. Güzelöz Z, Ayrancıoğlu O, Aktürk N, Güneş M, Alıcıkuş ZA. Dose Volume and Liver Function Test Relationship following Radiotheraphy for Right Breast Cancer: A Multicenter Study. Curr Oncol. 2023;30(10):8763-8773. doi: 10.3390/curroncol30100632. [DOI:10.3390/curroncol30100632] [PMID] []
8. Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75(3):291-4. [DOI:10.1016/j.jbspin.2007.06.016] [PMID]
9. Milovanovic M, Nilsson E, Järemo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta. 2004;343(1-2):237-40. [DOI:10.1016/j.cccn.2003.12.030] [PMID]
10. Yang WM, Zhang WH, Ying HQ, et al. Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: Albumin to fibrinogen ratio and C-reactive protein to albumin ratio. Int Immunopharmacol. 2018;62:293-8. doi: 10.1016/j.intimp.2018.07.007. [DOI:10.1016/j.intimp.2018.07.007] [PMID]
11. Li S, Su J, Cai W, Liu JX. Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment. Front Pharmacol. 2021;12:699245. doi: 10.3389/fphar.2021.699245. [DOI:10.3389/fphar.2021.699245] [PMID] []
12. Bridgewood C, Russell T, Weedon H, et al. The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clin Immunol. 2019;208:108253. doi: 10.1016/j.clim.2019.108253. [DOI:10.1016/j.clim.2019.108253] [PMID]
13. Abd Ali BM, Sharquie IK, Gorial FI. IL-41: A novel serum marker correlates with disease activity in patients with ankylosing spondylitis. Med J Malaysia. 2024 Nov;79(6):777-84.
14. CARY, N. Statistical analysis system, User's guide. Statistical. Version 9. SAS. Inst. Inc. USA, 2012.
15. Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313-7. doi: 10.1007/s13304-017-0424-1. [DOI:10.1007/s13304-017-0424-1] [PMID]
16. Paluch-ShimonS, CardosoF, PartridgeAH, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol. 2020;31(6):674-96. doi: 10.1016/j.annonc.2020.03.284. [DOI:10.1016/j.annonc.2020.03.284] [PMID]
17. Ning C, Li YY, Wang Y, et al. Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axis. Mucosal Immunol. 2015;8(6):1275-84. doi: 10.1038/mi.2015.18. [DOI:10.1038/mi.2015.18] [PMID]
18. Brown T, Sykes D, Allen AR. Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines. 2021;9(2):189. doi: 10.3390/biomedicines9020189. [DOI:10.3390/biomedicines9020189] [PMID] []
19. Shi R, He M, Peng Y, Xia X. Homotherapy for heteropathy: Interleukin-41 and its biological functions. Immunology. 2024 Sep;173(1):1-13. doi: 10.1111/imm.13791. [DOI:10.1111/imm.13791] [PMID]
20. Hu C, Zhang X, Song P, Yuan YP, Kong CY, Wu HM, Xu SC, Ma ZG, Tang QZ. Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway. Redox Biol. 2020 Oct;37:101747. doi: 10.1016/j.redox.2020.101747. [DOI:10.1016/j.redox.2020.101747] [PMID] []
21. Diamond JR, Finlayson CA, Borges VF. Hepatic complications of breast cancer. Lancet Oncol. 2009;10(6):615-21. [DOI:10.1016/S1470-2045(09)70029-4] [PMID]
22. Sannappa Gowda NG, Shiragannavar VD, Puttahanumantharayappa LD, Shivakumar AT, Dallavalasa S, Basavaraju CG, Bhat SS, Prasad SK, Vamadevaiah RM, Madhunapantula SV, Santhekadur PK. Quercetin activates vitamin D receptor and ameliorates breast cancer induced hepatic inflammation and fibrosis. Front Nutr. 2023 20;10:1158633. doi: 10.3389/fnut.2023.1158633. [DOI:10.3389/fnut.2023.1158633] [PMID] []
23. Ali A H, Abdusalam F M, Abdullah F M, & Abdulrahim E A. Study of some liver function tests in patients with breast carcinoma during chemotherapy treatment at oncology center in sebha city. Journal of Pure & Applied Sciences. 2020;19(5):68-73. doi:10.51984/jopas.v19i5.815
24. Manore SG, Doheny DL, Wong GL, Lo HW. IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. Front Oncol. 2022 Mar 15;12:866014. doi: 10.3389/fonc.2022.866014. [DOI:10.3389/fonc.2022.866014] [PMID] []
25. Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020 Feb;43(1):1-18. doi: 10.1007/s13402-019-00489-1. [DOI:10.1007/s13402-019-00489-1] [PMID]
26. Wang L, Simons DL, Lu X, Tu TY, Avalos C, Chang AY, Dirbas FM, Yim JH, Waisman J, Lee PP. Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine. 2020;52:102631. doi: 10.1016/j.ebiom.2020.102631. [DOI:10.1016/j.ebiom.2020.102631] [PMID] []
27. Ushach I, Arrevillaga-Boni G, Heller GN, Pone E, Hernandez-Ruiz M, Catalan-Dibene J, Hevezi P, Zlotnik A. Meteorin-like/Meteorin-β Is a Novel Immunoregulatory Cytokine Associated with Inflammation. J Immunol. 2018 Dec 15;201(12):3669-76. doi: 10.4049/jimmunol.1800435. [DOI:10.4049/jimmunol.1800435] [PMID] []
28. Ushach I, Burkhardt AM, Martinez C, Hevezi PA, Gerber PA, Buhren BA, Schrumpf H, Valle-Rios R, Vazquez MI, Homey B, Zlotnik A. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol. 2015 Feb;156(2):119-27. doi: 10.1016/j.clim.2014.11.006. [DOI:10.1016/j.clim.2014.11.006] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
